Talus Bio

Talus Bio is a biotechnology company dedicated to drug discovery focused on transcription factors (TFs), which play a crucial role in regulating gene expression and are linked to various diseases, including cancer and neurological disorders. The company aims to address the challenges of targeting TFs, often deemed "undruggable," by utilizing its innovative MARMOT platform. The MARMOT platform employs functional proteomics, automated biology, machine learning, and chemoproteomics to enhance drug discovery. This technology allows for high-throughput screening and the analysis of large datasets to identify potential druggable sites. Talus Bio's initial therapeutic programs concentrate on oncology, specifically targeting prostate cancer and Brachyury-driven cancers, with plans to expand into other areas such as inflammatory and neurological diseases. In August 2024, Talus Bio successfully raised $11.2 million in funding, indicating strong investor interest. The company is also focused on forming strategic collaborations to further its mission of modulating genome-regulating proteins.